Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' FATEHMOGHADAM A' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 40 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. RITZKE C; STIEBER P; UNTCH M; NAGEL D; EIERMANN W; FATEHMOGHADAM A
      ALKALINE-PHOSPHATASE ISOENZYMES IN DETECTION AND FOLLOW-UP OF BREAST-CANCER METASTASES

      Anticancer research
    2. REITER W; STIEBER P; SCHMELLER N; NAGEL D; SCHAMBECK C; FATEHMOGHADAM A
      IS FREE PROSTATE-SPECIFIC ANTIGEN HELPFUL IN THE DIFFERENTIAL-DIAGNOSIS OF BENIGN HYPERPLASIA AND CANCER OF THE PROSTATE

      Tumor biology
    3. REITER W; STIEBER P; SCHMELLER N; NAGEL D; HOFMANN K; FATEHMOGHADAM A
      TOTAL AND FREE PSA - A METHODICAL AND CLINICAL-EVALUATION OF 5 ASSAYS

      Anticancer research
    4. REITER W; STIEBER P; SCHMELLER N; NAGEL D; FATEHMOGHADAM A
      ALPHA(1)-ANTICHYMOTRYPSIN-PSA (ACT-PSA) - A USEFUL MARKER IN THE DIFFERENTIAL-DIAGNOSIS OF BENIGN HYPERPLASIA AND CANCER OF THE PROSTATE

      Anticancer research
    5. REITER W; STIEBER P; REUTER C; NAGEL D; CRAMER C; PAHL H; FATEHMOGHADAM A
      PROGNOSTIC VALUE OF PREOPERATIVE SERUM LEVELS OF CEA CA-19-9 AND CA-72-4 IN GASTRIC-CARCINOMA

      Anticancer research
    6. REITER W; STIEBER P; REUTER C; NAGEL D; LAUWERNER U; PAHL H; FATEHMOGHADAM A
      PREOPERATIVE SERUM LEVELS OF CEA AND CA-19-9 AND THEIR PROGNOSTIC-SIGNIFICANCE IN COLORECTAL-CARCINOMA

      Anticancer research
    7. MEIER W; STIEBER P; HASHOLZNER U; GROPP M; FATEHMOGHADAM A
      PROGNOSTIC-SIGNIFICANCE OF CA125 IN PATIENTS WITH OVARIAN-CANCER AND SECONDARY DEBULKING SURGERY

      Anticancer research
    8. MEIER W; BAUMGARTNER L; STIEBER P; HASHOLZNER U; FATEHMOGHADAM A
      SIGNIFICANCE OF TUMOR-MARKER DETERMINATIONS IN THE PRIMARY THERAPY OFOVARIAN-CANCER

      Anticancer research
    9. MEIER W; STIEBER P; HASHOLZNER U; BAUMGARTNER L; FATEHMOGHADAM A
      PROGNOSTIC-SIGNIFICANCE OF SQUAMOUS-CELL CARCINOMA (SCC) ANTIGEN IN PRIMARY ADVANCED AND RECURRENT CERVICAL-CARCINOMA

      Anticancer research
    10. WAIDELICH R; JANSEN HM; STIEBER P; SCHMELLER N; LAMERZ R; WERDAN K; FATEHMOGHADAM A
      SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE-SPECIFIC ANTIGEN

      Anticancer research
    11. REITER W; STIEBER P; SCHMELLER N; NAGEL D; JANSEN HM; SCHAMBECK C; FABRICIUS PG; PAHL H; MATTES M; CONSTABEL H; FATEHMOGHADAM A
      THE RATIO OF FREE TO TOTAL PROSTATE-SPECIFIC ANTIGEN - AN ADVANTAGEOUS ADDITION IN THE DIFFERENTIAL-DIAGNOSIS OF BENIGN HYPERPLASIA AND CANCER OF THE PROSTATE

      Anticancer research
    12. MEIER W; BAUMGARTNER L; STIEBER P; HASHOLZNER U; FATEHMOGHADAM A
      CA125 BASED DIAGNOSIS AND THERAPY IN RECURRENT OVARIAN-CANCER

      Anticancer research
    13. POLEY S; STIEBER P; NUSSLER V; PAHL H; FATEHMOGHADAM A
      EVALUATION OF SERUM NEURAL CELL-ADHESION MOLECULE AS A PROGNOSTIC MARKER IN MULTIPLE-MYELOMA

      Anticancer research
    14. POLEY S; STIEBER P; NUSSLER V; PAHL H; FATEHMOGHADAM A
      SERUM THYMIDINE KINASE IN NON-HODGKIN LYMPHOMAS WITH SPECIAL REGARD TO MULTIPLE-MYELOMA

      Anticancer research
    15. SCHAMBECK CM; STIEBER P; SCHMELLER N; HOFMANN K; PAHL H; FATEHMOGHADAM A
      CYFRA-21-1 QUANTITY MEASUREMENT IN THE URINE OF PATIENTS WITH CARCINOMA OF THE URINARY-BLADDER AND TRACT

      Anticancer research
    16. WICK M; WICK M; HEBERGER S; SIMON H; FATEHMOGHADAM A
      QUALITY STUDIES FOR PROTEIN-ANALYSIS OF I GG PREPARATIONS

      Infusionstherapie und Transfusionsmedizin
    17. SCHMITT UM; STIEBER P; HASHOLZNER U; PAHL H; HOFMANN K; FATEHMOGHADAM A
      METHODOLOGICAL AND CLINICAL-EVALUATION OF 2 AUTOMATED ENZYMATIC IMMUNOASSAYS AS COMPARED WITH A RADIOIMMUNOASSAY FOR NEURON-SPECIFIC ENOLASE

      European journal of clinical chemistry and clinical biochemistry
    18. STIEBER P; WOLLENBERG B; SCHMITT UM; VONJAN N; HOFMANN K; FATEHMOGHADAM A
      CLINICAL RELEVANCE OF TUMOR-MARKERS IN HE AD AND NECK SQUAMOUS-CELL CARCINOMAS

      Tumordiagnostik & Therapie
    19. HASHOLZNER U; STIEBER P; DIENEMANN H; FIEBIG M; FABRICIUS PG; MELER W; REUTER C; FATEHMOGHADAM A
      CHROMOGRANIN-A IN BENIGN AND MALIGNANT DISEASES

      Tumordiagnostik & Therapie
    20. REITER W; STIEBER P; SCHMELLER N; NAGEL D; PAHL H; MATTES M; FABRICIUS PG; FATEHMOGHADAM A
      FREE PSA - A USEFUL MARKER IN THE DIFFERENTIAL-DIAGNOSIS OF BENIGN HYPERPLASIA AND CANCER OF THE PROSTATE

      Tumordiagnostik & Therapie
    21. STIEBER P; SCHMELLER N; SCHAMBECK C; HOFMANN K; REITER W; HASHOLZNER U; FATEHMOGHADAM A
      CLINICAL RELEVANCE OF CYFRA-21-1, TPA-IRMA AND TPA-LIA-MAT IN URINARY-BLADDER CANCER

      Anticancer research
    22. WOLLENBERG B; JAN V; SCHMIT UM; HOFMANN K; STIEBER P; FATEHMOGHADAM A
      CYFRA-21-1 IS NOT SUPERIOR TO SCC ANTIGEN AND CEA IN HEAD AND NECK SQUAMOUS-CELL CANCER

      Anticancer research
    23. HASHOLZNER U; BAUMGARTNER L; STIEBER P; MEIER W; REITER W; PAHL H; FATEHMOGHADAM A
      CLINICAL-SIGNIFICANCE OF THE TUMOR-MARKERS CA-125-II AND CA-72-4 IN OVARIAN-CARCINOMA

      International journal of cancer
    24. SCHAMBECK CM; BARTL R; HOCHTLENVOLLMAR W; WICK M; LAMERZ R; FATEHMOGHADAM A
      CHARACTERIZATION OF MYELOMA CELLS BY MEANS OF LABELING INDEX, BONE-MARROW HISTOLOGY, AND SERUM BETA(2)-MICROGLOBULIN

      American journal of clinical pathology
    25. REITER W; STIEBER P; REUTER C; NAGEL D; CRAMER C; FATEHMOGHADAM A
      SENSITIVITY AND PROGNOSTIC-SIGNIFICANCE OF CA-72-4, CEA, AND CA-19-9 SERUM LEVELS IN UNTREATED PATIENTS WITH GASTRIC-CANCER

      Tumordiagnostik & Therapie
    26. SCHAMBECK CM; SCHMELLER N; STIEBER P; JANSEN HM; PAHL H; SCHNEIDER W; FATEHMOGHADAM A
      METHODOLOGICAL AND CLINICAL COMPARISON OF THE ACS PROSTATE-SPECIFIC ANTIGEN-ASSAY AND THE TANDEM-E PROSTATE-SPECIFIC ANTIGEN-ASSAY IN PROSTATE-CANCER

      Urology
    27. SCHAMBECK CM; WICK M; BARTL R; LAMERZ R; FATEHMOGHADAM A
      PLASMA-CELL PROLIFERATION IN MONOCLONAL GAMMOPATHIES - MEASUREMENT USING BU-1 ANTIBODY IN FLOW-CYTOMETRY AND MICROSCOPY - COMPARISON WITH SERUM THYMIDINE KINASE

      Journal of Clinical Pathology
    28. EBERT W; DIENEMANN H; FATEHMOGHADAM A; SCHEULEN M; KONIETZKO N; SCHLEICH T; BOMBARDIERI E
      CYTOKERATIN-19 FRAGMENT CYFRA-21-1 COMPARED WITH CARCINOEMBRYONIC ANTIGEN, SQUAMOUS-CELL CARCINOMA ANTIGEN AND NEURON-SPECIFIC ENOLASE IN LUNG-CANCER - RESULTS OF AN INTERNATIONAL MULTICENTER STUDY

      European journal of clinical chemistry and clinical biochemistry
    29. POLEY S; STIEBER P; PAHL H; FATEHMOGHADAM A
      EVALUATING A NEW BETA(2)-MICROGLOBULIN ENZYME-IMMUNOASSAY

      Tumordiagnostik & Therapie
    30. HASHOLZNER U; STIEBER P; BAUMGARTNER L; PAHL H; MEIER W; FATEHMOGHADAM A
      METHODICAL AND CLINICAL-EVALUATION OF 3 AUTOMATIZED CA 125 ASSAYS COMPARED WITH THE CA 125 II RIA

      Tumordiagnostik & Therapie
    31. POLEY S; FATEHMOGHADAM A; NUSSLER V; PAHL H
      SERUM BETA(2)-MICROGLOBULIN FOR STAGING AND MONITORING OF MULTIPLE MYELOMAS AND OTHER NON-HODGKIN LYMPHOMAS

      Onkologie
    32. WITHOLD W; WICK M; FATEHMOGHADAM A; EINHAUPL K
      DETECTION OF OLIGOCLONAL IGA IN CEREBROSPINAL-FLUID SAMPLES BY AN ISOELECTRIC-FOCUSING PROCEDURE

      Journal of neurology
    33. HASHOLZNER U; BAUMGARTNER L; STIEBER P; MEIER W; HOFMANN K; FATEHMOGHADAM A
      SIGNIFICANCE OF THE TUMOR-MARKERS CA-125-II, CA-72-4, CASA AND CYFRA-21-1 IN OVARIAN-CARCINOMA

      Anticancer research
    34. WICK M; FATEHMOGHADAM A
      LABORATORY DIAGNOSIS OF IMMUNODEFICIENCY

      Infusionstherapie und Transfusionsmedizin
    35. DIEM H; FATEHMOGHADAM A; LAMERZ R
      PROGNOSTIC FACTORS IN MULTIPLE-MYELOMA - ROLE OF BETA-2-MICROGLOBULINAND THYMIDINE KINASE

      The Clinical investigator
    36. STIEBER P; DIENEMANN H; HASHOLZNER U; MULLER C; POLEY S; HOFMANN K; FATEHMOGHADAM A
      COMPARISON OF CYTOKERATIN FRAGMENT 19 (CYFRA 21-1), TISSUE POLYPEPTIDE ANTIGEN (TPA) AND TISSUE POLYPEPTIDE SPECIFIC ANTIGEN (TPS) AS TUMOR-MARKERS IN LUNG-CANCER

      European journal of clinical chemistry and clinical biochemistry
    37. MEIER W; STIEBER P; FATEHMOGHADAM A; HEPP H
      CA-125 HALFLIFE AS NEW PROGNOSTIC FACTOR IN OVARIAN-CANCER

      Archives of gynecology and obstetrics
    38. BAUMGARTNER L; MEIER W; STIEBER P; FATEHMOGHADAM A; EIERMANN W; HEPP H
      VALUE OF TUMOR-MARKER CA-125 AS A PROGNOS TIC PARAMETER IN RECURRENT OVARIAN-CANCER

      Archives of gynecology and obstetrics
    39. STIEBER P; BODENMULLER H; BANAUCH D; HASHOLZNER U; DESSAUER A; OFENLOCHHAHNLE B; JAWOREK D; FATEHMOGHADAM A
      CYTOKERATIN 19 FRAGMENTS - A NEW MARKER FOR NON-SMALL-CELL LUNG-CANCER

      Clinical biochemistry
    40. STIEBER P; HASHOLZNER U; BODENMULLER H; NAGEL D; SUNDERPLASSMANN L; DIENEMANN H; MEIER W; FATEHMOGHADAM A
      CYFRA 21-1 - A NEW MARKER IN LUNG-CANCER

      Cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 04:57:06